Pharming Group N.V.
PHAR
$8.37
$0.05620.68%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
3/30/2025
-
MarketBeat
3/28/2025
-
Globe Newswire
3/25/2025
-
MarketBeat
3/22/2025
-
MarketBeat
3/21/2025
-
Ticker Report
3/21/2025
-
MarketBeat
3/20/2025
-
MarketBeat
3/20/2025
-
TipRanks Financial Blog
3/20/2025
-
TipRanks Financial Blog
3/20/2025
-
Globe Newswire
3/19/2025
-
Ticker Report
3/18/2025
-
MarketBeat
3/18/2025
-
Tickeron - Technical Analysis
3/18/2025
-
Tickeron - Technical Analysis
3/15/2025
-
MarketBeat
3/15/2025
-
Ticker Report
3/15/2025
-
MarketBeat
3/14/2025
-
Ticker Report
3/14/2025
-
MarketBeat
3/14/2025
-
MarketBeat
3/14/2025
-
GuruFocus
3/14/2025
-
GuruFocus
Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
3/13/2025
-
SeekingAlpha.com: All News
3/13/2025
-
Seeking Alpha: Transcripts
3/13/2025
-
SeekingAlpha
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, August 1, 2024
Period Date
Sunday, June 30, 2024
Next Filing
(est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
31 71 524 7400
Address
Darwinweg 24
Leiden, 2333 CR
Leiden, 2333 CR
Country
Year Founded
Business Description
Sector
--
Industry
--
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States...
more
